CA2938671A1 - Donepezil compositions and method of treating alzheimer's disease - Google Patents

Donepezil compositions and method of treating alzheimer's disease Download PDF

Info

Publication number
CA2938671A1
CA2938671A1 CA2938671A CA2938671A CA2938671A1 CA 2938671 A1 CA2938671 A1 CA 2938671A1 CA 2938671 A CA2938671 A CA 2938671A CA 2938671 A CA2938671 A CA 2938671A CA 2938671 A1 CA2938671 A1 CA 2938671A1
Authority
CA
Canada
Prior art keywords
donepezil
pharmaceutically acceptable
acceptable salt
memantine
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2938671A
Other languages
English (en)
French (fr)
Inventor
Mahendra G. Dedhiya
Kavita Vermani
Ashok Katdare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forest Laboratories Holdings ULC
Original Assignee
Forest Laboratories Holdings ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53753905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2938671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Laboratories Holdings ULC filed Critical Forest Laboratories Holdings ULC
Priority to CA3214846A priority Critical patent/CA3214846A1/en
Publication of CA2938671A1 publication Critical patent/CA2938671A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
CA2938671A 2014-02-04 2015-02-04 Donepezil compositions and method of treating alzheimer's disease Pending CA2938671A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3214846A CA3214846A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and methods of treating alzheimer's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461935596P 2014-02-04 2014-02-04
US61/935,596 2014-02-04
PCT/US2015/014404 WO2015120013A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and method of treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3214846A Division CA3214846A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and methods of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
CA2938671A1 true CA2938671A1 (en) 2015-08-13

Family

ID=53753905

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2938671A Pending CA2938671A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and method of treating alzheimer's disease
CA3214846A Pending CA3214846A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and methods of treating alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3214846A Pending CA3214846A1 (en) 2014-02-04 2015-02-04 Donepezil compositions and methods of treating alzheimer's disease

Country Status (7)

Country Link
US (2) US20150216849A1 (enExample)
EP (1) EP3102186B1 (enExample)
JP (2) JP6604957B2 (enExample)
CA (2) CA2938671A1 (enExample)
IL (2) IL247092B (enExample)
MX (1) MX383665B (enExample)
WO (1) WO2015120013A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3102186B1 (en) 2014-02-04 2021-01-27 Forest Laboratories Holdings Limited Donepezil compositions and method of treating alzheimer's disease
WO2018035157A1 (en) * 2016-08-15 2018-02-22 Axovant Sciences Gmbh Compositions and methods of treating a neurodegenerative disease
WO2018153315A1 (zh) 2017-02-23 2018-08-30 上海华汇拓医药科技有限公司 一种多奈哌齐半帕莫酸盐的粉针剂、包含其的组合物及它们的制备方法
WO2020068731A1 (en) * 2018-09-25 2020-04-02 The General Hospital Corporation Methods for integrating cell gene expression data from multiple single-cell data sets and uses thereof
WO2020208398A1 (es) * 2019-04-09 2020-10-15 Laboratorios Bagó S.A. Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10966989B2 (en) * 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
WO2022270663A1 (ko) * 2021-06-23 2022-12-29 동아에스티 주식회사 도네페질, 실로스타졸 및 아리피프라졸을 포함하는 치매, 인지장애 또는 혈관성 우울증의 예방, 개선 또는 치료용 약학적 조성물
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
WO2023128890A1 (en) * 2021-12-28 2023-07-06 Ilko Ilac Sanayi Ve Ticaret A.S. Donepezil – memantine extended release capsule composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH603545A5 (enExample) 1972-04-20 1978-08-31 Merz & Co
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
ES2059602T3 (es) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
EA012220B1 (ru) 2004-10-19 2009-08-28 Крка, Товарна Здравил, Д. Д., Ново Место Твёрдая фармацевтическая композиция, содержащая донепезила гидрохлорид
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
JP5666087B2 (ja) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
JP5597343B2 (ja) * 2005-04-28 2014-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有する組成物
CN101304764B (zh) * 2005-11-11 2012-12-05 旭化成化学株式会社 控释固体制剂
GR20070100405A (el) 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
WO2009084017A2 (en) 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
TWI491395B (zh) 2009-09-30 2015-07-11 Ct Lab Inc 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
CN102309465B (zh) * 2010-06-30 2015-04-22 天津药物研究院 含盐酸多奈哌齐活性成分的缓释片及其制备方法和用途
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
US20140243278A1 (en) * 2011-07-05 2014-08-28 Sunil Sadanand Nadkarni Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
EP3102186B1 (en) 2014-02-04 2021-01-27 Forest Laboratories Holdings Limited Donepezil compositions and method of treating alzheimer's disease

Also Published As

Publication number Publication date
MX383665B (es) 2025-03-14
JP6604957B2 (ja) 2019-11-13
EP3102186A1 (en) 2016-12-14
IL247092B (en) 2020-08-31
IL247092A0 (en) 2016-09-29
US20180169082A1 (en) 2018-06-21
EP3102186A4 (en) 2017-06-28
JP2017506624A (ja) 2017-03-09
EP3102186B1 (en) 2021-01-27
JP2020037556A (ja) 2020-03-12
MX2016010179A (es) 2017-04-06
IL276315A (en) 2020-09-30
US20150216849A1 (en) 2015-08-06
CA3214846A1 (en) 2015-08-13
WO2015120013A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
EP3102186B1 (en) Donepezil compositions and method of treating alzheimer's disease
AU2019204689B2 (en) Solid dosage forms of palbociclib
AU2011220813B2 (en) Abuse-resistant formulations
US9474721B2 (en) Abuse-resistant formulations
JP6739470B2 (ja) デフェラシロクスの経口製剤
JP2009545557A (ja) 胃保持性のデリバリーシステム
KR20150043497A (ko) 약제 함유 할로우 입자
CA3029543C (en) Immediate release pharmaceutical composition of iron chelating agents
RS53087B (sr) Čvrste farmaceutske kompozicije stalnog sastava koje sadrže irbesartan i amlodipin, njihovo dobijanje i terapijska primena
US20130146496A1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
US20140044780A1 (en) Extended-Release Levetiracetam and Method of Preparation
KR102270521B1 (ko) 구토억제 서방형 고체 제형
WO2011143120A1 (en) Alcoholres i stant metoprolol - containing extended - release oral dosage forms
JP6866136B2 (ja) デュロキセチン塩酸塩を含む口腔内崩壊錠
CN105106963B (zh) 马来酸曲美布汀缓释制剂及其制备方法
Mehta et al. Formulation and development of lenalidomide loaded delayed release mini tablets in capsules
WO2015140709A1 (en) Solid pharmaceutical dosage forms
JP6211044B2 (ja) 薬物含有中空粒子
Gupta Formulation Development And Evalution Of Immediate Release Tablet of Anti Hypertensive Drug Olmesartan Medoxomile.
Kim et al. Formulation and Evaluation of Sustained Release Preparation of Ibuprofen Fast-Disintegrating Tablet (FDT)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200131

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20240717

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250915

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260318